BidaskClub lowered shares of Flexion Therapeutics (NASDAQ:FLXN) from a sell rating to a strong sell rating in a report published on Saturday morning, BidAskClub reports.
A number of other equities analysts have also recently weighed in on the stock. Wells Fargo & Co reaffirmed a buy rating and set a $26.00 price target on shares of Flexion Therapeutics in a research note on Friday, December 28th. Benchmark cut shares of Flexion Therapeutics from a buy rating to a hold rating and set a $11.49 price target on the stock. in a research note on Friday, January 4th. Needham & Company LLC reaffirmed a buy rating and set a $36.00 price target (down from $42.00) on shares of Flexion Therapeutics in a research note on Friday, January 4th. BMO Capital Markets lowered their price target on shares of Flexion Therapeutics from $36.00 to $34.00 and set an outperform rating on the stock in a research note on Friday, January 4th. Finally, Zacks Investment Research raised shares of Flexion Therapeutics from a sell rating to a hold rating in a research note on Wednesday, February 6th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Flexion Therapeutics currently has a consensus rating of Hold and an average price target of $22.64.
NASDAQ:FLXN opened at $10.56 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 7.58 and a current ratio of 7.78. Flexion Therapeutics has a fifty-two week low of $9.90 and a fifty-two week high of $29.10. The firm has a market cap of $404.59 million, a PE ratio of -2.35 and a beta of 1.68.
In other Flexion Therapeutics news, insider Michael D. Clayman acquired 4,046 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were purchased at an average cost of $12.36 per share, with a total value of $50,008.56. Following the purchase, the insider now owns 70,856 shares in the company, valued at $875,780.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.59% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Carroll Financial Associates Inc. grew its stake in Flexion Therapeutics by 100.0% in the 4th quarter. Carroll Financial Associates Inc. now owns 2,000 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,000 shares during the last quarter. Next Capital Management LLC acquired a new stake in Flexion Therapeutics in the 4th quarter valued at about $84,000. Advisor Group Inc. grew its stake in Flexion Therapeutics by 68.2% in the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock valued at $97,000 after acquiring an additional 3,490 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its stake in Flexion Therapeutics by 341.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,455 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 8,084 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its stake in Flexion Therapeutics by 4.9% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 16,668 shares of the specialty pharmaceutical company’s stock valued at $189,000 after acquiring an additional 772 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.